{"disease":{"id":"antiviral-drug-adverse-reaction","name":"antiviral drug adverse reaction"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03775798","title":"Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.","phase":"","overall_status":"UNKNOWN","enrollment_count":2200,"lead_sponsor_name":"Austral University, Argentina","has_results":false},{"nct_id":"NCT03566030","title":"Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral Resistance","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT03296930","title":"Effect Of DAAs For Treatment Of HCV On Normal Kidney","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT03251144","title":"Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT04340388","title":"Contribution of Dolutegravir to Obesity and Cardiovascular Disease","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Augusta University","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}